X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Biocon Ltd with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ACTAVIS (US) - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 BIOCON    ACTAVIS
EQUITY SHARE DATA
    BIOCON
Mar-18
ACTAVIS
Dec-18
BIOCON /
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,18813,317-   
Low Rs3058,933-   
Sales per share (Unadj.) Rs68.73,266.6-  
Earnings per share (Unadj.) Rs7.6-1,052.2-  
Cash flow per share (Unadj.) Rs14.0344.2-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.313,473.1-  
Shares outstanding (eoy) m600.00332.60-   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.93.4 319.0%   
Avg P/E ratio x98.9-10.6 -934.9%  
P/CF ratio (eoy) x53.432.3 165.3%  
Price / Book Value ratio x8.60.8 1,047.0%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,9003,700,093 12.1%   
No. of employees `0006.116.9 36.4%   
Total wages/salary Rs m9,3110-   
Avg. sales/employee Rs Th6,705.864,287.7 10.4%   
Avg. wages/employee Rs Th1,514.20-   
Avg. net profit/employee Rs Th736.9-20,707.1 -3.6%   
INCOME DATA
Net Sales Rs m41,2341,086,461 3.8%  
Other income Rs m2,06220,777 9.9%   
Total revenues Rs m43,2961,107,238 3.9%   
Gross profit Rs m8,29128,471 29.1%  
Depreciation Rs m3,851464,439 0.8%   
Interest Rs m61562,695 1.0%   
Profit before tax Rs m5,887-477,886 -1.2%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0121,880 0.0%   
Tax Rs m1,569-6,056 -25.9%   
Profit after tax Rs m4,531-349,950 -1.3%  
Gross profit margin %20.12.6 767.3%  
Effective tax rate %26.71.3 2,103.1%   
Net profit margin %11.0-32.2 -34.1%  
BALANCE SHEET DATA
Current assets Rs m41,486445,610 9.3%   
Current liabilities Rs m21,413394,201 5.4%   
Net working cap to sales %48.74.7 1,028.8%  
Current ratio x1.91.1 171.4%  
Inventory Days Days6420 326.6%  
Debtors Days Days9466 142.0%  
Net fixed assets Rs m50,661122,981 41.2%   
Share capital Rs m3,0000-   
"Free" reserves Rs m48,8080-   
Net worth Rs m51,8084,481,145 1.2%   
Long term debt Rs m17,8981,577,974 1.1%   
Total assets Rs m99,8977,005,050 1.4%  
Interest coverage x10.6-6.6 -159.6%   
Debt to equity ratio x0.30.4 98.1%  
Sales to assets ratio x0.40.2 266.1%   
Return on assets %5.2-4.1 -125.6%  
Return on equity %8.7-7.8 -112.0%  
Return on capital %9.6-4.8 -199.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m4,7100-   
CASH FLOW
From Operations Rs m6,621388,152 1.7%  
From Investments Rs m-6,840213,239 -3.2%  
From Financial Activity Rs m-2,397-666,184 0.4%  
Net Cashflow Rs m-2,612-64,471 4.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.82 Rs / USD

Compare BIOCON With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare BIOCON With: ABBOTT INDIA  FDC LTD.  CADILA HEALTHCARE  IPCA LABS  PANACEA BIOTECH  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views On News

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks (Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock (The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jul 19, 2019 (Close)

TRACK BIOCON

BIOCON - STRIDES PHARMA SCIENCE COMPARISON

COMPARE BIOCON WITH

MARKET STATS